Kathrin Zitzmann

Franz Josef Strauss Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

[68Ga]Ga-DOTATATE uptake in pheochromocytoma/paraganglioma predicts SSTR2 expression by immunohistochemistry: Strongest uptake in head and neck paraganglioma.

[68Ga]Ga-DOTATATE uptake in pheochromocytoma/paraganglioma predicts SSTR2 expression by immunohistochemistry: Strongest uptake in head and neck paraganglioma.

Journal: European journal of nuclear medicine and molecular imaging
Published: December 22, 2025

GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors.

GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors.

Journal: Biology open
Published: November 18, 2025

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.

Journal: The Journal of clinical endocrinology and metabolism
Published: October 15, 2025

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours.

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours.

Journal: Endocrine oncology (Bristol, England)
Published: April 27, 2025

Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures.

Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures.

Journal: Endocrine-related cancer
Published: March 07, 2025

Long-Term Persistence of Glycemic Dysregulation in Patients With a History of Pheochromocytoma/Paraganglioma.

Long-Term Persistence of Glycemic Dysregulation in Patients With a History of Pheochromocytoma/Paraganglioma.

Journal: The Journal of clinical endocrinology and metabolism
Published: October 29, 2024

Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.

Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.

Journal: Oncoimmunology
Published: October 08, 2024

Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors.

Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors.

Journal: European journal of endocrinology
Published: June 28, 2024

Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells with Combined Inhibition of Class I HDACs and LSD1.

Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells with Combined Inhibition of Class I HDACs and LSD1.

Journal: Neuroendocrinology
Published: May 22, 2024

Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures.

Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures.

Journal: The Journal of clinical endocrinology and metabolism
Published: January 19, 2024

PD-L1 and HIF-2α Upregulation in Head and Neck Paragangliomas after Embolization.

PD-L1 and HIF-2α Upregulation in Head and Neck Paragangliomas after Embolization.

Journal: Cancers
Published: October 11, 2023

Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System.

Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System.

Journal: Cancers
Published: June 26, 2023
Showing 1-12 of 19

Last Updated: 09/26/2026